TennCare - As enacted, authorizes the bureau to provide coverage and treatment on behalf of an enrollee for the diagnosis, including genetic testing, and treatment of Kleefstra syndrome in the same manner and to the same extent that the bureau provides coverage for autism spectrum disorder, Trisomy 21 or Down syndrome, and other similar or related genetic disorders, when determined to be medically necessary. - Amends TCA Title 56 and Title 71.

SB 522 requires Tennessee's TennCare program to cover diagnosis (including genetic testing) and treatment for Kleefstra syndrome - a rare genetic disorder causing developmental delays, intellectual disability, and physical symptoms - on the same terms as coverage for autism spectrum disorder, Down syndrome, and similar genetic conditions. This mandate applies directly to TennCare enrollees diagnosed with Kleefstra syndrome, ensuring access to therapies, medications, and interventions aimed at improving quality of life. The bill updates TennCare coverage rules to include this condition under existing standards for comparable genetic disorders. It takes effect July 1, 2025.